Reliability and validity of a new HIV-specific questionnaire with adults living with HIV in Canada and Ireland: the HIV Disability Questionnaire (HDQ)

Health and Quality of Life Outcomes

Ahmed M. Bayoumi¹  Nkem Iku³  Paul Stratford⁴  Siobhán O’Dea²  Colm Bergin⁵  Patricia Solomon⁴  Kelly K. O’Brien⁴ 

[1] Department of Medicine, University of Toronto, Toronto, ON, Canada;Department of Genito Urinary Medicine and Infectious Diseases, Hospital 5, St. James’s Hospital, James’s Street, Dublin 8, Ireland;Department of Physical Therapy, University of Toronto, 500 University Avenue, Room 160, Toronto M5G 1V7, ON, Canada;School of Rehabilitation Science, McMaster University, 1400 Main Street West, Room 408, Hamilton L8S 1C7, ON, Canada;Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland

关键词: Reliability;    Validity;    Questionnaire;    Disability;    HIV/AIDS;   

Others  :  1224724
DOI  :  10.1186/s12955-015-0310-9

 received in 2014-09-05, accepted in 2015-07-20,  发布年份 2015

【 摘 要 】

Background

Our aim was to assess internal consistency reliability, construct validity, and test-retest reliability of the HDQ with adults living with HIV in Canada and Ireland.

Methods

We recruited adults 18 years of age or older living with HIV from hospital clinics and AIDS service organizations in Canada and Ireland. We administered the HDQ paired with reference measures (World Health Organization Disability Assessment Schedule, SF-36 Questionnaire, Medical Outcomes Study Social Support Survey), and a demographic questionnaire. We calculated HDQ disability presence, severity and episodic scores (scored from 0–100). We calculated Cronbach’s alpha and Intraclass Correlation Coefficients (ICC) (Canada only) for the disability severity and episodic scores and considered coefficients >0.80 and >0.70 as acceptable, respectively. To assess construct validity, we tested 40 a priori hypotheses of correlations between scores on the HDQ and reference measures and two known group hypotheses comparing HDQ presence and severity scores based on age and comorbidity. We considered acceptance of at least 75 % of hypotheses as demonstrating support for construct validity.

Results

Of the 235 participants (139 Canada; 96 Ireland), the majority were men (74 % Ireland; 82 % Canada) and were taking antiretroviral therapy (88 % Ireland; 91 % Canada). Compared with Irish participants, Canadian participants were older (median age: 48 versus 41 years) and reported living with a higher median number of comorbidities (4 versus 1). Cronbach’s alpha for Irish and Canadian participants were 0.97 (95 % confidence interval (CI): 0.97–0.98) and 0.96 (95 % CI: 0.95–0.98), respectively, for the severity scale and 0.98 (95 % CI: 0.97–0.98) and 0.96 (95 % CI: 0.95–0.98), respectively, for the episodic scale. Of the 40 construct validity correlation hypotheses, 32 (80 %) and 22 (55 %) were supported among the Canadian and Irish samples respectively; both (100 %) known group hypotheses were also supported. ICC values for Canadian participants ranged from 0.80 (95 % CI: 0.71, 0.86) in the cognitive domain to 0.89 (95 % CI: 0.83, 0.92) in the social inclusion domain.

Conclusions

The HDQ demonstrates internal consistency reliability and a variable degree of construct validity when administered to adults living with HIV in Canada and Ireland. The HDQ demonstrates test-retest reliability when administered to adults with HIV in Canada. Further validation of the HDQ outside of Canada is needed.

【 授权许可】

   
2015 O’Brien et al.

【 参考文献 】

• [1]Public Health Agency of Canada: Summary: Estimates of HIV Prevalence and Incidence in Canada. 2011. Available at:. http://webqa. phac-aspc.gc.ca/aids-sida/publication/survreport/estimat2011-eng.php webcite
• [2]AVERT. AVERTing HIV and AIDS: European HIV and AIDS Statistics. 2011. Available at:. http://www. avert.org/european-hiv-aids-statistics.htm webcite
• [3]HIV in Ireland, 2013. Health Protection Surveillance Centre, Dublin; 2014.
• [4]Goodroad BK. HIV and AIDS in people older than 50. A continuing concern. J Gerontol Nurs. 2003; 29:18-24.
• [5]Justice AC. HIV and aging: time for a new paradigm. Curr HIV/AIDS Rep. 2010; 7:69-76.
• [6]Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53:1120–6.
• [7]Mallon PW. Aging with HIV: osteoporosis and fractures. Curr Opin HIV AIDS. 2014; 9:428-435.
• [8]Kendall CE, Wong J, Taljaard M, Glazier RH, Hogg W, Younger J et al.. A cross-sectional, population-based study measuring comorbidity among people living with HIV in Ontario. BMC Public Health. 2014; 14:161. BioMed Central Full Text
• [9]O’Brien KK, Bayoumi AM, Strike C, Young NL, Davis AM. Exploring disability from the perspective of adults living with HIV/AIDS: development of a conceptual framework. Health Qual Life Outcomes. 2008; 6:76. BioMed Central Full Text
• [10]O’Brien KK, Bayoumi AM, Strike C, Young NL, King K, Davis AM. How do existing HIV-specific instruments measure up? Evaluating the ability of instruments to describe disability experienced by adults living with HIV. Health Qual Life Outcomes. 2010; 8:88. BioMed Central Full Text
• [11]Palella FJ, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT et al.. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006; 43:27-34.
• [12]Duracinsky M, Lalanne C, Le Coeur S, Herrmann S, Berzins B, Armstrong AR et al.. Psychometric validation of the PROQOL-HIV questionnaire, a new health-related quality of life instrument-specific to HIV disease. J Acquir Immune Defic Syndr. 2012; 59:506-515.
• [13]Duracinsky M, Herrmann S, Berzins B, Armstrong AR, Kohli R, Le Coeur S et al.. The development of PROQOL-HIV: an international instrument to assess the health-related quality of life of persons living with HIV/AIDS. J Acquir Immune Defic Syndr. 2012; 59:498-505.
• [14]Mayo NE, Wood-Dauphinee S, Ahmed S, Gordon C, Higgins J, McEwen S et al.. Disablement following stroke. Disabil Rehabil. 1999; 21:258-268.
• [15]Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA. 1995; 273:59-65.
• [16]O’Brien KK, Bayoumi AM, King K, Alexander R, Solomon P. Community engagement in health status instrument development: experience with the HIV disability questionnaire. Prog Community Health Partnersh. 2014; 8:549-559.
• [17]O’Brien KK, Davis AM, Strike C, Young NL, Bayoumi AM. Putting episodic disability into context: a qualitative study exploring factors that influence disability experienced by adults living with HIV/AIDS. J Int AIDS Soc. 2009; 12:5. BioMed Central Full Text
• [18]O’Brien KK, Bayoumi AM, Bereket T, Swinton M, Alexander R, King K et al.. Sensibility assessment of the HIV disability questionnaire. Disabil Rehabil. 2013; 35(7):566-77.
• [19]World Health Organizations Disability Assessment Schedule II (WHO-DAS-II). World Health Organization, Geneva; 2001.
• [20]Berger BE, Ferrans CE, Lashley FR. Measuring stigma in people with HIV: Psychometric assessment of the HIV stigma scale. Res Nurs Health. 2001; 24:518-529.
• [21]Carver CS. You want to measure coping but your protocol’s too long: consider the brief COPE. Int J Behav Med. 1997; 4:92-100.
• [22]Justice AC, Holmes W, Gifford AL, Rabeneck L, Zackin R, Sinclair G, et al. Development and validation of a self-completed HIV symptom Index. J Clin Epidemiol. 2001;54:S77–90.
• [23]Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977; 1:385-401.
• [24]Sherbourne CD, Stewart AL. The MOS social support survey. Soc Sci Med. 1991; 32:705-714.
• [25]Ware JE, Gandek B. Overview of the SF-36 health survey and the International Quality of Life Assessment (IQOLA) project. J Clin Epidemiol. 1998; 51:903-912.
• [26]O’Brien KK, Bayoumi AM, Stratford P, Solomon P. Which dimensions of disability does the HIV Disability Questionnaire (HDQ) measure? A factor analysis. Disabil Rehabil. 2014; 37:1-9.
• [27]Kemmler G, Schmied B, Shetty-Lee A, Zangerle R, Hinterhuber H, Schussler G et al.. Quality of life of HIV-infected patients: psychometric properties and validation of the German version of the MQOL-HIV. Qual Life Res. 2003; 12:1037-1050.
• [28]Meesters JJ, Verhoef J, Liem IS, Putter H, Vliet Vlieland TP. Validity and responsiveness of the World Health Organization Disability Assessment Schedule II to assess disability in rheumatoid arthritis patients. Rheumatology (Oxford). 2010; 49:326-333.
• [29]Lyon DE, Younger JB. Purpose in life and depressive symptoms in persons living with HIV disease. J Nurs Scholarsh. 2001; 33:129-133.
• [30]Burack JH, Barrett DC, Stall RD, Chesney MA, Ekstrand ML, Coates TJ. Depressive symptoms and CD4 lymphocyte decline among HIV-infected men. JAMA. 1993; 270:2568-2573.
• [31]Chishinga N, Kinyanda E, Weiss HA, Patel V, Ayles H, Seedat S. Validation of brief screening tools for depressive and alcohol use disorders among TB and HIV patients in primary care in Zambia. BMC Psychiatry. 2011; 11:75. BioMed Central Full Text
• [32]Lyketsos CG, Hoover DR, Guccione M, Senterfitt W, Dew MA, Wesch J et al.. Depressive symptoms as predictors of medical outcomes in HIV infection. Multicenter AIDS Cohort Study. JAMA. 1993; 270:2563-2567.
• [33]Cook JA, Grey D, Burke J, Cohen MH, Gurtman AC, Richardson JL et al.. Depressive symptoms and AIDS-related mortality among a multisite cohort of HIV-positive women. Am J Public Health. 2004; 94:1133-1140.
• [34]Ware JE. SF-36 health survey update. Spine (Phila Pa 1976). 2000; 25:3130-3139.
• [35]McHorney CA, Ware JE, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993; 31:247-263.
• [36]McHorney CA, Ware JE, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994; 32:40-66.
• [37]McHorney CA, Tarlov AR. Individual-patient monitoring in clinical practice: are available health status surveys adequate? Qual Life Res. 1995; 4:293-307.
• [38]Corp IBM. SPSS Statistics for Windows, Version 19.0. IBM Corp, Armonk, NY; 2010.
• [39]SAS Institute Inc.: SAS Computer Software 9.2. 2008.
• [40]Nunnally JC, Bernstein IH. Psychometric Theory. 3rd ed. McGraw-Hill, New York; 1978.
• [41]Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977; 33:159-174.
• [42]Shen S, Lu Z: Computation of Correlation Coefficient and Its Confidence Interval in SAS®. AstraZeneca Pharmaceuticals. Wilmington, Delaware. Avaiable at:. http://www2. sas.com/proceedings/sugi31/170-31.pdf webcite
• [43]Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J et al.. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol. 2007; 60:34-42.
• [44]Aaronson N, Alonso J, Burnam A, Lohr KN, Patrick DL, Perrin E et al.. Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res. 2002; 11:193-205.
• [45]Browner WS, Newman TB, Cummings SR, Hulley SB.  Chapter 6: Estimating sample size and power: The nitty-gritty. In: Designing Clinical Research. 2nd ed. Editors: Hulley SB, Cummings SR, Browner WS, Grady D, Hearst N, Newman TB. Philadelphia, PA: Lippincott Williams & Wilkins; 2001.
• [46]O’Brien KK, Solomon P, Bayoumi AM. Measuring disability experienced by adults living with HIV: assessing construct validity of the HIV Disability Questionnaire using confirmatory factor analysis. BMJ Open. 2014; 4: Article ID e005456
• [47]Shaw SJ, Huebner C, Armin J, Orzech K, Vivian J. The role of culture in health literacy and chronic disease screening and management. J Immigr Minor Health. 2009; 11:460-467.
• [48]Epstein J, Santo RM, Guillemin F. A review of guidelines for cross-cultural adaptation of questionnaires could not bring out a consensus. J Clin Epidemiol. 2015; 68:435-441.
• [49]Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine (Phila Pa 1976). 2000; 25:3186-3191.
• [50]Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL et al.. The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. Qual Life Res. 2010; 19:539-549.
• [51]Solomon P, O’Brien K, Wilkins S, Gervais N. Aging with HIV and disability: the role of uncertainty. AIDS Care. 2014; 26:240-245.
• [52]Fluctuating symptoms of HIV. National AIDS Trust, United Kingdom; 2011.
• [53]Farber EW, Schwartz JA, Schaper PE, Moonen DJ, McDaniel JS. Resilience factors associated with adaptation to HIV disease. Psychosomatics. 2000; 41:140-146.
• [54]Emlet CA, Tozay S, Raveis VH. “I’m not going to die from the AIDS”: resilience in aging with HIV disease. Gerontologist. 2011; 51:101-111.